CAJ | 학술논문

单倍体移植治疗恶性血液病的临床研究
단배체이식치료악성혈액병적림상연구
Clinical study of haploidentical hematopoietic stem cell transplantation as a treatment of hematopoietic malignancies

万方数据

中国医药中國醫藥 중국의약
CHINA MEDICINE
2010年 9期 837-839 ,共3页

王智明%王琳%陈晓霞%罗贤生%何丽莉%黄姿英%符容香%王云英%黎丽琼%谭莲%徐丹丹%李兴

왕지명%왕림%진효하%라현생%하려리%황자영%부용향%왕운영%려려경%담련%서단단%리흥

血液肿瘤%造血干细胞移植%单倍性血液腫瘤%造血榦細胞移植%單倍性
혈액종류%조혈간세포이식%단배성
Hematologic neoplasms%Hematopoietic stem cell transplantation%Haploidy

目的探讨单倍体移植治疗恶性血液病的疗效.方法在单倍体移植时采用阿糖胞苷、马利兰、环磷酰胺、甲基环已亚硝脲联合作为预处理方案,用环磷酰胺、重组人粒细胞集落刺激因子、环孢素、麦考酚酸酯、抗胸腺细胞球蛋白、白细胞介素11及甲氨蝶呤联合预防急性移植物抗宿主病(aGVHD),治疗8例恶性血液病患者.结果 8例患者完全植入,白细胞＞1.0×109/L中位时间为16.3 d(+12～+20 d),Ⅲ～Ⅳ度aGVHD的发生率为12.5%,中位随访时间28.8(4-65)个月,无复发,随访至2010年2月仍存活.结论在单倍体移植治疗恶性血液病时采用阿糖胞苷、马利兰、环磷酰胺、甲基环己亚硝脲联合作为预处理方案,用环磷酰胺、重组人粒细胞集落刺激因子、环孢素、麦考酚酸酯、抗胸腺细胞球蛋白、白细胞介素11及甲氨蝶呤联合预防aGVHD是一种安全、有效的方法.
목적 탐토단배체이식치료악성혈액병적료효.방법 재단배체이식시채용아당포감、마리란、배린선알、갑기배이아초뇨연합작위예처리방안,용배린선알、중조인립세포집락자격인자、배포소、맥고분산지、항흉선세포구단백、백세포개소11급갑안접령연합예방급성이식물항숙주병(aGVHD),치료8례악성혈액병환자.결과 8례환자완전식입,백세포＞1.0×109/L중위시간위16.3 d(+12～+20 d),Ⅲ～Ⅳ도aGVHD적발생솔위12.5%,중위수방시간28.8(4-65)개월,무복발,수방지2010년2월잉존활.결론 재단배체이식치료악성혈액병시채용아당포감、마리란、배린선알、갑기배기아초뇨연합작위예처리방안,용배린선알、중조인립세포집락자격인자、배포소、맥고분산지、항흉선세포구단백、백세포개소11급갑안접령연합예방aGVHD시일충안전、유효적방법.
Objective To study the effect of haploidentical hematopoietic stem cell transplantation as a treatment of hematopoietic malignancies. Methods We used cytosine arabinoside ( Ara-c) , busulphan ( Bu) , cyclophosphamide (CTX) and methyl ccnu (MeCCNU) as preconditioning of patients and then we used cyclophosphamide(CTX), rhG-CSF, cyclosporine A ( CSA ), mycophenolate mofetil ( MMF), the anti-thymocyte globulin ( ATG) , IL-11 and methotrexate( MTX) as prophylaxis of acute graft versus host diseases to treat 8 cases of hematopoietic malignancies. Results All patients achieved complete engraftment. The median times of neutrophil recovery > 1.0 ×109/L were 16. 3 (12～20)days after transplantation. The incidence of grade Ⅲ～Ⅳ aGVHD was 12.5%. All patients survived disease-free with a median follow-up of 28. 8 (4～65) months. Conclusions Haploidentical hematopoietic stem cell transplantation is a safe and effective treatment for hematopoietic malignancies, with Ara-c, Bu, CTX, MeCCNU as preconditioning and CTX, rhG-CSF, CSA, MMF, ATG, IL-11 and MTX as prophylaxis of aGVHD.